Khaled Musallam Applauds Hatoon Ezzat’s Leadership and Healthcare Advances in Saudi Arabia
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, reposted from Thalassaemia International Federation (TIF) on LinkedIn:
”Very impressed with all the tech and regulatory advances deployed by the Ministry of Health Saudi Arabia and the leadership of Dr Hatoon Ezzat dedicated to the management of inherited blood disorders in general and thalassemia in specific. Outcomes from such initiatives will surely have global implications on disease understanding and care.”
Quoting Thalassaemia International Federation (TIF)‘s post:
”High-Level TIF–Kingdom of Saudi Arabia Strategic Meeting | 14 December 2025
A high-level delegation of the Thalassaemia International Federation – TIF held a strategic meeting on 14 December 2025 with senior representatives of the Ministry of Health Saudi Arabia, underscoring a shared commitment to accelerating progress in the prevention, control, and comprehensive management of thalassaemia and other haemoglobinopathies.
The TIF delegation comprised Dr. Androulla Eleftheriou, TIF Executive Director; Prof. john porter, Professor of Haematology and Consultant Haematologist at University College London Hospitals (UK); Prof. Khaled Musallam, MD, PhD, Group Chief Research Officer of Burjeel Holdings and Founding Director of CR-RBD (UAE); and Prof. Dimitrios Farmakis, MD, PhD, FESC, FHFA, Professor of Cardiology at the National and Kapodistrian University of Athens (Greece), members of TIF’s International Scientific Advisory Board.
The delegates met with H.E. Dr. Mohammed K. Alabdulaali, Assistant Deputy Minister for Hospital Services; Dr. Hatoon Ezzat, Assistant Minister’s Advisor and General Supervisor of Blood Disorders; and Prof. Ahmad Tarawah, Consultant in Pediatric Hematology/Oncology.
During the discussions, TIF congratulated the Government of the KSA on its notable progress in strengthening national systems for the control and management of thalassaemia and other haemoglobinopathies, as well as on the impressive outcomes of its health-sector digitaltransformation.
Particular emphasis was placed on advancing integrated digital health ecosystems and strengthening datasystems, enabling smarter service planning, better follow-up, improved continuity of care, and a more streamlined patientjourney across different levels of the health system.
TIF also commended the KSA’s leadership in facilitating access to healthinnovation, including its distinction as the first country globally to authorise the novel oral therapy PYRUKYND® (mitapivat) for adult patients with transfusion-dependent (TDT) and non-transfusion-dependent (NTDT) α- or β-thalassaemia.
Building on an already excellent and long-standing collaboration between TIF and the KSA, the meeting also explored a forward-looking agenda of joint initiatives.
These include co-developed educational activities and collaborative actions that could support regional and international efforts to improve standards of care and outcomes for patients and their families.”
Stay updated with Hemostasis Today.
-
Jan 13, 2026, 13:03Claudio Laudani on Dual Versus Single Antiplatelet Therapy
-
Jan 13, 2026, 12:46Stephanie Carlin and Colleagues on Clinical Outcomes of DOAC-Anticonvulsant Coprescription
-
Jan 13, 2026, 10:53Lena Volland on Ming Y Lim’s Example of Designing Care Models for WGBD Community With Intention
-
Jan 13, 2026, 05:05Pablo Corral Shares Key Takeaways on Reducing LDL-Cholesterol to Very Low Levels
-
Jan 13, 2026, 04:49Martin Haluzík Shares A Study on GLP1-1RAs Use in Peripheral Artery Disease and DM
-
Jan 13, 2026, 04:37Shreya Agarwal and Bryce A Kerlin on The Impact of Advanced Hemostasis and Thrombosis Fellowship Trainings
-
Jan 13, 2026, 03:53Christian Schulze Shares New Data from DANGERSHOCK
-
Jan 13, 2026, 03:39Samwel Mikaye Breaks Down Peripheral Blood Smear
-
Jan 12, 2026, 20:15Mazou Ngou Temgoua on SCAF: Subclinical Atrial Fibrillation on Treatment with Apixaban or Aspirin